New psoriasis drug shows promise in Mid-Stage trial
NCT ID NCT01585233
Summary
This study tested a new drug called ASKP1240 in people with moderate to severe plaque psoriasis. The main goals were to check the drug's safety, how it moves through the body, and if it could improve skin symptoms. About 60 participants received either the drug or a placebo over 4 weeks and were followed for 12 more weeks to monitor their health and skin condition.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Auckland Clinical Studies
Auckland, 1010, New Zealand
-
CMAX
Adelaide, Victoria, 5000, Australia
-
Christchurch Clincial Studies Trust, Ltd.
Christchurch, 8011, New Zealand
-
Durondel C.P. Inc, The Dermatology Clinic
Moncton, New Brunswick, E1C 8X3, Canada
-
Epworth Hospital
Richmond, Victoria, 3121, Australia
-
Innovaderm Research, Inc.
Montreal, Quebec, H2K 4L5, Canada
-
K. Papp Clinical Research
Waterloo, Ontario, N2J 1C4, Canada
-
Linear Research
Nedlands, Western Australia, 6009, Australia
-
New Lab Clinical Research
St. John's, Newfoundland and Labrador, A1C 2H5, Canada
-
P3 Research, Tauranga
Tauranga, 3110, New Zealand
-
P3 Research, Wellington
Wellington, 6021, New Zealand
-
Specialist Connect
Brisbane, Queensland, 4102, Australia
-
Ultranova Skincare
Barrie, Ontario, L4M 6L2, Canada
Conditions
Explore the condition pages connected to this study.